Lawmakers urge FDA to close loophole on imported knockoff obesity drug retatrutide

A bipartisan group of lawmakers is pressing the FDA to close a regulatory loophole that allows importation of counterfeit versions of Eli Lilly's investigational obesity drug retatrutide. The move signals growing concern over unregulated peptide imports and potential safety risks, though the FDA's response remains uncertain. This could impact the market for legitimate obesity treatments and regulatory enforcement.